Differential associations between actual and expected GP practice prescribing rates for statins, ACE inhibitors, and beta-blockers: a cross-sectional study in England
Authors Paul R Ward, Peter R Noyce, Antony S St Leger
Published Date January 2005 Volume 2005:1(1) Pages 61—68
Published 20 January 2005
Paul R Ward1, Peter R Noyce2, Antony S St Leger3
1School of Health and Related Research, University of Sheffield, England, UK; 2School of Pharmacy and Pharmaceutical Sciences, University of Manchester, England, UK; 3School of Epidemiology and Health Sciences, University of Manchester, England, UK
Aim: To explore the relationship between actual and expected general medical practitioner (GP) practice prescribing rates for statins, angiotensin converting enzyme (ACE) inhibitors, and beta-blockers.
Background: There is a growing body of literature highlighting inequities in GP practice prescribing rates for many drug therapies. The equity of prescribing is of central importance in the area of therapeutics since it explores the interface between those patients who should and those who actually do receive a drug therapy.
Setting: Four primary care trusts (PCTs 1–4) in the North West of England, including 132 GP practices.
Methods: Actual and expected prescribing rates for statins, beta-blockers, and ACE inhibitors were specifically developed for each GP practice.
Results: There were no statistically significant correlations between actual and expected prescribing rates in PCT2 and PCT3, although in PCT1 there were statistically significant correlations for statins (0.286, p < 0.05) and ACE inhibitors (0.381, p < 0.01). In PCT4, correlations were moderate to high for beta-blockers (0.693, p < 0.01), and moderate for statins (0.541, p < 0.05) and ACE inhibitors (0.585, p < 0.01). Scatterplots highlighted large variations between individual GP practices (both within and between PCTs) in terms of the relationship between actual and expected prescribing rates.
Conclusion: This paper highlights variability between PCTs and GP practices in terms of the relationship between actual and expected prescribing rates. The findings from this paper may further advance the suggestion of inequities in prescribing rates for coronary heart disease (CHD) drugs, and studies such as this may be repeated in different therapeutic areas, healthcare settings, and countries.
Keywords: prescribing rates, equity, coronary heart disease, statins, beta-blockers, ACE inhibitor
Readers of this article also read:
Osadnik CR, McDonald CF, Holland AE
Published Date: 25 March 2014
COPD management costs according to the frequency of COPD exacerbations in UK primary care [Corrigendum]
Punekar YS, Shukla A, Müllerova H
Published Date: 24 February 2014
Shahar E, Shahar DJ
Published Date: 22 January 2014
Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Corrigendum]
Dahl R, Jadayel D, Alagappan VKT, Chen H, Banerji D
Published Date: 16 January 2014
COPD exacerbations admitted to intensive care unit. Organization, mortality, and noninvasive or invasive mechanical ventilation strategies: are they sufficiently well known?
Published Date: 29 July 2013
Upper limit of the normal range for thyrotropin-stimulating hormone is higher with increasing age [Corrigendum]
Published Date: 26 April 2013
Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R
Published Date: 16 January 2013
Siebeling L, Puhan MA, Muggensturm P, Zoller M, ter Riet G
Published Date: 5 October 2012
Published Date: 9 August 2012